Genenta Science reports preliminary results of Temferon-glioblastoma study

May 24, 2022 -- Biotech company Genenta Science is developing a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers, according to co-founder Dr. Bernhard Gentner, PhD. spoke to Gentner at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC, about Temferon, which is under investigation in a phase I/IIa clinical trial in newly diagnosed glioblastoma multiforme patients.

"We have treated so far 16 patients with this strategy," Gentner said, noting that early results are promising with T cell response activation in some patients. "We did this in glioblastoma patients, which is really a terrible tumor which has no cure today."

Watch the video below to learn more.

Copyright © 2022

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.